Compare Eli Lilly And Co (LLY) vs ArcelorMittal SA (MT) Price & Performance

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.

LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.

ArcelorMittal (MT) trades at $61.30, down 1.64% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with declining revenue from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Analyst consensus remains positive with a $74.33 price target, but recent Ukraine plant impairments and steel demand concerns create headwinds. Technical indicators show oversold conditions with RSI at 12.65, while support sits at $59.

MT presents a cautious opportunity with 54.5% analyst buy ratings and attractive valuation multiples (P/S 0.75, P/B 0.84), but faces significant operational risks from geopolitical exposure and volatile steel markets. The $1B Ukraine impairment and declining cash flow trends offset margin improvements, requiring careful risk assessment for potential investors.